Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
to contribute to sustainable development. To this end, scholarships are granted for development-related Master or doctoral studies for individuals who plan to pursue a career in teaching and / or research at a
-
. The issues treated in the research project must be of high relevance to the continued development of the applicant's country or region of origin. Target Group highly qualified experienced researchers from a
-
well as professional and personal support. The scholarship holders are supported in their personal development with a large number of offers. This includes soft skill seminars and language courses as well as summer
-
of aerospace and to act as a centre of research, development and training. The Munich Aerospace unites 4 entities under one institutional roof: the TUM (Technical University Munich), the UniBwM (University
-
developing countries (KOSPIE)" with funds from the Federal Ministry for Economic Cooperation and Development (BMZ). As part of this programme, young students from Tunisia from engineering subjects (including a
-
well as key skills development. Target Group particularly gifted German and international doctoral candidates from any discipline completing promising doctoral dissertations at a German higher education
-
committee consisting of specialist scientists reviews the applications. The selection criteria are: Academic Qualification academic achievements (grade point average, development of grades) academic progress
-
closely with architects, engineers, biologists, and chemists at the University of Stuttgart and the University of Freiburg. The research focuses on the conception, development, and evaluation of bio
-
Academic achievements (grade point average, development of grades) Academic progress Knowledge of the language(s) of instruction or working language(s) If applicable, scholarly achievements after graduation
-
/progenitor cells. A clinically active p300/CREBBP inhibitor is currently in development and is expected to enter clinical trials in late 2026. PhD project: Targeting p300/CREBBP to Enhance Interferon Signaling